Uterine Fibroids

Surgery Without Incisions: New Frontiers for Radiology

Published in Medical Letter on the CDC and FDA, December 26th, 2004

InSightec's ExAblate 2000 Magnetic Resonance guided Focused Ultrasound (MRgFUS) system was introduced at the 90th Scientific Assembly and Annual Meeting of the Radiological Society of North America.

On October 22, 2004, the U.S. Food and Drug Administration (FDA) approved the ExAblate 2000 System for the treatment of uterine fibroids. It expedited its review of the device because "it offers significant advantages over existing treatments for uterine fibroids."

ExAblate uses a Magnetic Resonance Imaging (MRI) scanner to identify tissues in the body and assist in planning treatment. During the noninvasive surgical procedure, delivery of high intensity...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2004-12-26)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry